|1.||Korbelik, Mladen: 14 articles (09/2013 - 09/2002)|
|2.||Busch, Theresa M: 12 articles (12/2012 - 12/2002)|
|3.||Cecic, Ivana: 9 articles (10/2008 - 09/2002)|
|4.||Glatstein, Eli: 9 articles (09/2007 - 12/2002)|
|5.||Wolfsen, Herbert C: 8 articles (01/2010 - 02/2002)|
|6.||Kiesslich, Tobias: 6 articles (11/2015 - 06/2007)|
|7.||Berr, Frieder: 6 articles (11/2015 - 05/2004)|
|8.||Wang, Hsing-Wen: 6 articles (12/2009 - 10/2004)|
|9.||Wilson, Brian C: 6 articles (12/2008 - 01/2003)|
|10.||Hahn, Stephen M: 6 articles (09/2006 - 04/2003)|
01/01/2013 - "However, since FTC improves the efficacy of SDT in GSCs by inhibiting ABCG2-mediated efflux of Photofrin, FTC may be useful in SDT treatment of ABCG2-expressing cancer cells."
01/01/1993 - "Animals treated with photofrin II had a 1 month cancer-free survival of 27% while animals treated with BPD had an improved survival of 67% (P = 0.03). "
09/15/2006 - "A secondary aim of this trial and the subject of this report is to determine Photofrin uptake in tumor and normal tissues. "
01/01/2004 - "A study was designed to determine the pharmacokinetic profile and variability of porfimer sodium in dogs and cats with spontaneous tumors and to thereby determine the optimal timing of its photoactivation in these species. "
11/07/2003 - "The results of this study showed that Photofrin II can act, under certain conditions as a tumor radiosensitizer."
|2.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
06/01/1997 - "From this study, we conclude that photo-detection with Photofrin has potential in distinguishing chemically induced premalignant lesions and squamous cell carcinomas from the normal rat palatal mucosa. "
01/01/1993 - "The purpose of this study was to compare a new photosensitizing agent, benzoporphyrin derivative (BPD), to the standard agent presently in use, photofrin II, in a hamster cheek pouch model of squamous cell carcinoma. "
02/01/2013 - "However, efficient cell death still requires the combination of Photofrin and light irradiation in esophageal squamous cell carcinoma cells."
02/01/2013 - "Another esophageal squamous cell carcinoma cell line CE81T/VGH (CE81T) was found to be resistant to Photofrin-induced inhibition of EGFR as well as to Photofrin-mediated dark toxicity compared with CE48T. "
11/01/2010 - "Using human epidermoid carcinoma A431 cells as a model, we previously showed that distinct cell death types could be triggered by protocols that selectively delivered Photofrin (a clinically approved photosensitizer) to different subcellular sites (Hsieh et al.  J Cell Physiol 194: 363-375]. "
10/01/2013 - "Electric field-assisted delivery of photofrin to human breast carcinoma cells."
09/15/2004 - "Photofrin, a complex mixture of porphyrin oligomers has recently received FDA approval for the photodynamic treatment of esophageal and endobronchial carcinoma, but its photodynamic and toxicity profiles are far from ideal. "
10/01/2000 - "The sonodynamically induced antitumor effect of Photofrin II (PF), was evaluated in mice bearing colon 26 carcinoma. "
10/01/2000 - "Sonodynamically induced antitumor effect of Photofrin II on colon 26 carcinoma."
04/01/1996 - "Patient treatment--A 70-year-old woman with recurrent local rectal carcinoma received intravenous Photofrin II (2 mg/kg). "
|4.||Lung Neoplasms (Lung Cancer)
02/01/1990 - "Detection of early lung cancer using low dose Photofrin II."
10/01/1993 - "A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. "
01/01/2009 - "In vitro survival of nonsmall cell lung cancer cells following combined treatment with ionizing radiation and photofrin-mediated photodynamic therapy."
01/01/1996 - "Photodynamic therapy of lung cancer with bronchial artery infusion of photofrin."
03/17/1993 - "Phase III trials in esophageal cancer and lung cancer are in progress and will help in evaluation of whether Photofrin II, the most widely used sensitizer, can be added to the oncologic armamentarium, pending approval from the U.S. "
01/01/2013 - "We aimed to investigate the role of the ABCG2 transporter in the efficacy of sonodynamic therapy (SDT) with Photofrin in the glioma stem-like cells (GSCs) isolated and cultured from U251 glioma cells. "
01/01/2013 - "The ABCG2 transporter is a key molecular determinant of the efficacy of sonodynamic therapy with Photofrin in glioma stem-like cells."
12/01/2012 - "To elucidate the mechanism of the antitumor effects of SDT, we evaluated intracellular ROS production and Photofrin uptake: ROS production and Photofrin content were significantly lower (p < 0.01) in GSCs than in U251 glioma cells. "
12/01/2012 - "We attempted to compare the susceptibility of GSCs to SDT, using Photofrin, a porphyrin-derivative photosensitizer, with that of glioma cells. "
12/01/2012 - "Glioma stem-like cells are less susceptible than glioma cells to sonodynamic therapy with photofrin."
|2.||Dihematoporphyrin Ether (Porfimer Sodium)
|3.||Photosensitizing Agents (Photosensitizers)
|6.||Talaporfin (talaporfin sodium)
|9.||LDL-Receptor Related Protein 1 (LDL-Receptor Related Protein)
|10.||Poloxamer (Poloxamer 407)
|1.||Photochemotherapy (Photodynamic Therapy)
|3.||Drug Therapy (Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)